Lexeo Therapeutics, Inc. Cash Flow Statement
LXEO|1 years of annual SEC 10-K data (FY2023-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
Lexeo Therapeutics, Inc. used $55M in operating cash flow and negative free cash flow of $55M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Net Income | -$59.3M |
| Depreciation & Amortization | $120.0K |
| Operating Cash Flow | -$54.6M |
| Capital Expenditures | $672.0K |
| Free Cash Flow | -$55.2M |
| FCF Margin | -8445.3% |